ClinicalTrials.gg
CompletedNCT02155179Updated Aug 13, 2019

Sperm Pathology Samples and Morphokinetics

An observational study in Cylinical Embryo and Oligospermia, sponsored by IVI Madrid. Completed at 2 sites in Spain. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by IVI Madrid · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
112
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The embryo kinetics may be a new prognostic factor for choosing the embryos with the highest implantation potential. In order to identify the factors that may affect the rate of embryo cleavage, there are many studies about morphokinetics and culture medium, oxygen tension, oocyte quality or type of medication used for ovarian stimulation. However there are no published data with respect to the influence of semen quality in the embryo kinetic.

In this study The investigators propose that the sperm quality may has influence in the embryo division.

02

Conditions studied

  • Cylinical Embryo
  • Oligospermia

Browse trials for

03

In context

Oligospermia

64 studies on the registry are indexed under Oligospermia; 17 are open to participants now.

This study's enrollment of 112 is below the median of 300 across 17 observational studies indexed under Oligospermia.

Browse Oligospermia studies →

Lead sponsor

IVI Madrid is the lead sponsor of 35 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Sperms samples of assisted reproduction treatments

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sperm samples with more than 15 mill/ml of sperms, more than 40% of mobile sperms
  • Sperm samples with less than 5 mill/ml of sperms, less than 10% of mobile sperms

Exclusion criteria

Exclusion Criteria:

  • sperm samples between 5 to 15 mil/ml of sperms and between 10% to 40% of mobile sperms
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
112 participants (actual)
Patient registry
No

Groups and cohorts

  • Good prognosis

    Sperm samples \>15mill/ml \>30% progresive sperms

  • bad prognosis

    Sperm samples \<5mill/ml \<5% progresive sperms

06

What researchers measure

Primary outcomes

  1. embryo division in 2, 3, 4, 5, 6, 7, 8, cells and blastocyst formation

    Exact time of cell cleavages

    Time frame: between day 0 and day 5 of development

07

Study locations

2 sites
  • IVI MAdrid
    Madrid, 28023, Spain
  • Madrid, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2014
First posted
Jun 4, 2014
Start
Aug 2014
Primary completionActual
Dec 2018
CompletionActual
Dec 2018
Last update
Aug 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02155179
Lead sponsor
IVI Madrid
Responsible party
Sponsor
First posted
Jun 4, 2014
Start date
Aug 2014
Primary completion
Dec 2018
Completion
Dec 2018
Last update
Aug 13, 2019

Study contacts

david agudo, PhD
principal investigator · lab coordinator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion